

## Nomination of Iris Löw-Friedrich (64) as director<sup>(1)</sup>

### Education

1985	Medical School, Goethe University Frankfurt, MD
1985	Max Planck Institute for Physics, Germany, PhD, Biophysics

### Professional experience

<b>2001-2024</b>	<b>UCB</b>
2008-2024	Executive Vice President, Head of Development & Chief medical Officer, Belgium
2001-2007	Global Head of R&D, Schwarz Pharma, Germany
<b>2000-2001</b>	<b>BASF</b> , Vice President & head of Global Projects, Germany
<b>1992-2000</b>	<b>Sanofi</b>
1998-2000	Vice President & Head of Global Clinical Management, NJ, USA
1996-2000	Vice President & Head of Global Therapeutic Area Rheumatology, Immunology, Bone Disease, HMR Global Drug Development Center, NJ, USA
1992-1996	Clinical Research Physician, Study Director, Germany
<b>1985-2000</b>	<b>Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany</b>
1993-2000	Associate Professor, Internal Medicine
1985-1992	Staff Physician, Internal Medicine, Immunology, Nephrology & Transplantation Medicine

### Current Directors mandates

- Zogenix (since 2022)
- Evotec (Chairwoman, since 2021)
- TransCelerate BioPharma (since 2017)
- Fresenius (since 2016)

### Recommendation of the board of directors

The board of directors formulates a unanimous favourable advice on the candidature of Mrs. Iris Löw-Friedrich as director of the Company. Mrs. Iris Löw-Friedrich has the qualifications, skills, knowledge, experience and integrity to make a valuable contribution to the functioning of the board of directors. She committed to make sufficient time available for exercising her mandate.

(1) For a period of four years ending on the ordinary general meeting of 2029.